Note J - Equity-based Compensation - Stock Options, SARs and RSUs Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		12 Months Ended
		Sep. 30, 2020		Dec. 31, 2019
Outstanding at June 30, 2020 (in shares)		1,872
Outstanding at June 30, 2020 (in dollars per share)		$ 2.45
Outstanding at June 30, 2020 (Year)	[1]	3 years 8 months 19 days	[2]	3 years 11 months 19 days
Options granted (in shares)		0
Options granted, weighted average exercise price (in dollars per share)		$ 0
Options granted, aggregate intrinsic value	[3]
Options / SARs / RSUs cancelled/forfeited/expired (in shares)		(72)
Options / SARs / RSUs cancelled/forfeited/expired, weighted average exercise price (in dollars per share)		$ 0
Options / SARs exercised and RSUs vested (in shares)		(79)
Options / SARs exercised and RSUs vested, weighted average exercise price (in dollars per share)		$ 0.03
Outstanding (in shares)	[2]	1,813
Outstanding, weighted average exercise price (in dollars per share)	[2]	$ 2.52
Outstanding, aggregate value	[2],[3]	$ 19,323
Exercisable (in shares)	[4]	440
Exercisable, weighted average exercise price (in dollars per share)	[4]	$ 9.58
Exercisable, weighted average remaining contractual term (Year)	[1],[4]	3 years 8 months 15 days
Exercisable, aggregate value	[3],[4]	$ 1,581
Stock Appreciation Rights (SARs) [Member]
Non-option instruments granted (in shares)		0
Non-option instruments, weighted average exercise price (in dollars per share)		$ 0
Non-option instruments, aggregate intrinsic value	[3]
Restricted Stock Units (RSUs) [Member]
Non-option instruments granted (in shares)		92
Non-option instruments, weighted average exercise price (in dollars per share)		$ 0
Non-option instruments, aggregate intrinsic value	[3]

[1] Calculation of weighted average remaining contractual term does not include RSUs that were granted, which have indefinite contractual term.

[2] Due to the ceiling imposed on the SAR grants, the outstanding amount above can be exercised for a maximum of 1,773,000 shares of the Company’s common stock as of September 30, 2020. SAR grants made on or after January 1, 2012 are convertible for a maximum number of shares of the Company’s common stock equal to 50% of the SARs subject to the grant.

[3] Calculation of aggregate intrinsic value is based on the share price of the Company's common stock on September 30, 2020 ($13.18 per share).

[4] Due to the ceiling imposed on the SAR grants, the exercisable amount above can be exercised for a maximum of 411,000 shares of the Company’s common stock as of September 30, 2020.